Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses

Michelle Meyer, Tania Garron, Ndongala M. Lubaki, Chad Mire, Karla A. Fenton, Curtis Klages, Gene G. Olinger, Thomas Geisbert, Peter L. Collins, Alexander Bukreyev

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Direct delivery of aerosolized vaccines to the respiratory mucosa elicits both systemic and mucosal responses. This vaccine strategy has not been tested for Ebola virus (EBOV) or other hemorrhagic fever viruses. Here, we examined the immunogenicity and protective efficacy of an aerosolized human parainfluenza virus type 3-vectored vaccine that expresses the glycoprotein (GP) of EBOV (HPIV3/EboGP) delivered to the respiratory tract. Rhesus macaques were vaccinated with aerosolized HPIV3/EboGP, liquid HPIV3/EboGP, or an unrelated, intramuscular, Venezuelan equine encephalitis replicon vaccine expressing EBOV GP. Serum and mucosal samples from aerosolized HPIV3/EboGP recipients exhibited high EBOV-specific IgG, IgA, and neutralizing antibody titers, which exceeded or equaled titers observed in liquid recipients. The HPIV3/EboGP vaccine induced an EBOV-specific cellular response that was greatest in the lungs and yielded polyfunctional CD8<sup>+</sup> T cells, including a subset that expressed CD103 (αE integrin), and CD4<sup>+</sup> T helper cells that were predominately type 1. The magnitude of the CD4<sup>+</sup> T cell response was greater in aerosol vaccinees. The HPIV3/EboGP vaccine produced a more robust cell-mediated and humoral immune response than the systemic replicon vaccine. Moreover, 1 aerosol HPIV3/EboGP dose conferred 100% protection to macaques exposed to EBOV. Aerosol vaccination represents a useful and feasible vaccination mode that can be implemented with ease in a filovirus disease outbreak situation.

Original languageEnglish (US)
Pages (from-to)3241-3255
Number of pages15
JournalJournal of Clinical Investigation
Volume125
Issue number8
DOIs
StatePublished - Aug 3 2015

Fingerprint

Ebola Vaccines
Ebolavirus
Primates
Vaccines
T-Lymphocytes
Lung
Aerosols
Human parainfluenza virus 3
Replicon
Glycoproteins
Vaccination
Venezuelan Equine Encephalomyelitides
Respiratory Mucosa
Macaca
Humoral Immunity
Helper-Inducer T-Lymphocytes
Neutralizing Antibodies
Macaca mulatta
Integrins
Respiratory System

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses. / Meyer, Michelle; Garron, Tania; Lubaki, Ndongala M.; Mire, Chad; Fenton, Karla A.; Klages, Curtis; Olinger, Gene G.; Geisbert, Thomas; Collins, Peter L.; Bukreyev, Alexander.

In: Journal of Clinical Investigation, Vol. 125, No. 8, 03.08.2015, p. 3241-3255.

Research output: Contribution to journalArticle

Meyer, M, Garron, T, Lubaki, NM, Mire, C, Fenton, KA, Klages, C, Olinger, GG, Geisbert, T, Collins, PL & Bukreyev, A 2015, 'Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses', Journal of Clinical Investigation, vol. 125, no. 8, pp. 3241-3255. https://doi.org/10.1172/JCI81532
Meyer, Michelle ; Garron, Tania ; Lubaki, Ndongala M. ; Mire, Chad ; Fenton, Karla A. ; Klages, Curtis ; Olinger, Gene G. ; Geisbert, Thomas ; Collins, Peter L. ; Bukreyev, Alexander. / Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses. In: Journal of Clinical Investigation. 2015 ; Vol. 125, No. 8. pp. 3241-3255.
@article{49224db329224fd59b446e138cc70aed,
title = "Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses",
abstract = "Direct delivery of aerosolized vaccines to the respiratory mucosa elicits both systemic and mucosal responses. This vaccine strategy has not been tested for Ebola virus (EBOV) or other hemorrhagic fever viruses. Here, we examined the immunogenicity and protective efficacy of an aerosolized human parainfluenza virus type 3-vectored vaccine that expresses the glycoprotein (GP) of EBOV (HPIV3/EboGP) delivered to the respiratory tract. Rhesus macaques were vaccinated with aerosolized HPIV3/EboGP, liquid HPIV3/EboGP, or an unrelated, intramuscular, Venezuelan equine encephalitis replicon vaccine expressing EBOV GP. Serum and mucosal samples from aerosolized HPIV3/EboGP recipients exhibited high EBOV-specific IgG, IgA, and neutralizing antibody titers, which exceeded or equaled titers observed in liquid recipients. The HPIV3/EboGP vaccine induced an EBOV-specific cellular response that was greatest in the lungs and yielded polyfunctional CD8+ T cells, including a subset that expressed CD103 (αE integrin), and CD4+ T helper cells that were predominately type 1. The magnitude of the CD4+ T cell response was greater in aerosol vaccinees. The HPIV3/EboGP vaccine produced a more robust cell-mediated and humoral immune response than the systemic replicon vaccine. Moreover, 1 aerosol HPIV3/EboGP dose conferred 100{\%} protection to macaques exposed to EBOV. Aerosol vaccination represents a useful and feasible vaccination mode that can be implemented with ease in a filovirus disease outbreak situation.",
author = "Michelle Meyer and Tania Garron and Lubaki, {Ndongala M.} and Chad Mire and Fenton, {Karla A.} and Curtis Klages and Olinger, {Gene G.} and Thomas Geisbert and Collins, {Peter L.} and Alexander Bukreyev",
year = "2015",
month = "8",
day = "3",
doi = "10.1172/JCI81532",
language = "English (US)",
volume = "125",
pages = "3241--3255",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "8",

}

TY - JOUR

T1 - Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses

AU - Meyer, Michelle

AU - Garron, Tania

AU - Lubaki, Ndongala M.

AU - Mire, Chad

AU - Fenton, Karla A.

AU - Klages, Curtis

AU - Olinger, Gene G.

AU - Geisbert, Thomas

AU - Collins, Peter L.

AU - Bukreyev, Alexander

PY - 2015/8/3

Y1 - 2015/8/3

N2 - Direct delivery of aerosolized vaccines to the respiratory mucosa elicits both systemic and mucosal responses. This vaccine strategy has not been tested for Ebola virus (EBOV) or other hemorrhagic fever viruses. Here, we examined the immunogenicity and protective efficacy of an aerosolized human parainfluenza virus type 3-vectored vaccine that expresses the glycoprotein (GP) of EBOV (HPIV3/EboGP) delivered to the respiratory tract. Rhesus macaques were vaccinated with aerosolized HPIV3/EboGP, liquid HPIV3/EboGP, or an unrelated, intramuscular, Venezuelan equine encephalitis replicon vaccine expressing EBOV GP. Serum and mucosal samples from aerosolized HPIV3/EboGP recipients exhibited high EBOV-specific IgG, IgA, and neutralizing antibody titers, which exceeded or equaled titers observed in liquid recipients. The HPIV3/EboGP vaccine induced an EBOV-specific cellular response that was greatest in the lungs and yielded polyfunctional CD8+ T cells, including a subset that expressed CD103 (αE integrin), and CD4+ T helper cells that were predominately type 1. The magnitude of the CD4+ T cell response was greater in aerosol vaccinees. The HPIV3/EboGP vaccine produced a more robust cell-mediated and humoral immune response than the systemic replicon vaccine. Moreover, 1 aerosol HPIV3/EboGP dose conferred 100% protection to macaques exposed to EBOV. Aerosol vaccination represents a useful and feasible vaccination mode that can be implemented with ease in a filovirus disease outbreak situation.

AB - Direct delivery of aerosolized vaccines to the respiratory mucosa elicits both systemic and mucosal responses. This vaccine strategy has not been tested for Ebola virus (EBOV) or other hemorrhagic fever viruses. Here, we examined the immunogenicity and protective efficacy of an aerosolized human parainfluenza virus type 3-vectored vaccine that expresses the glycoprotein (GP) of EBOV (HPIV3/EboGP) delivered to the respiratory tract. Rhesus macaques were vaccinated with aerosolized HPIV3/EboGP, liquid HPIV3/EboGP, or an unrelated, intramuscular, Venezuelan equine encephalitis replicon vaccine expressing EBOV GP. Serum and mucosal samples from aerosolized HPIV3/EboGP recipients exhibited high EBOV-specific IgG, IgA, and neutralizing antibody titers, which exceeded or equaled titers observed in liquid recipients. The HPIV3/EboGP vaccine induced an EBOV-specific cellular response that was greatest in the lungs and yielded polyfunctional CD8+ T cells, including a subset that expressed CD103 (αE integrin), and CD4+ T helper cells that were predominately type 1. The magnitude of the CD4+ T cell response was greater in aerosol vaccinees. The HPIV3/EboGP vaccine produced a more robust cell-mediated and humoral immune response than the systemic replicon vaccine. Moreover, 1 aerosol HPIV3/EboGP dose conferred 100% protection to macaques exposed to EBOV. Aerosol vaccination represents a useful and feasible vaccination mode that can be implemented with ease in a filovirus disease outbreak situation.

UR - http://www.scopus.com/inward/record.url?scp=84938719389&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938719389&partnerID=8YFLogxK

U2 - 10.1172/JCI81532

DO - 10.1172/JCI81532

M3 - Article

C2 - 26168222

AN - SCOPUS:84938719389

VL - 125

SP - 3241

EP - 3255

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 8

ER -